JP4685861B2 - ドーパミンアゴニストとしての３−ピペリジニルイソクロマン−５−オール - Google Patents

ドーパミンアゴニストとしての３−ピペリジニルイソクロマン−５−オール Download PDF

Info

Publication number
JP4685861B2
JP4685861B2 JP2007510941A JP2007510941A JP4685861B2 JP 4685861 B2 JP4685861 B2 JP 4685861B2 JP 2007510941 A JP2007510941 A JP 2007510941A JP 2007510941 A JP2007510941 A JP 2007510941A JP 4685861 B2 JP4685861 B2 JP 4685861B2
Authority
JP
Japan
Prior art keywords
methyl
isochroman
piperidin
aminomethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007510941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535548A (ja
JP2007535548A5 (enExample
Inventor
グレゴリー・シュツケ
キース・ジェイ・ハリス
ケネス・ジェイ・ボードー
マイクル・アール・アンジェラストロ
スタンリー・ジョン
ジョゼフ・ティー・クレイン
ジンキ・ルー
カサリン・ボーモント
Original Assignee
アベンティス・ファーマスーティカルズ・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アベンティス・ファーマスーティカルズ・インコーポレイテツド filed Critical アベンティス・ファーマスーティカルズ・インコーポレイテツド
Publication of JP2007535548A publication Critical patent/JP2007535548A/ja
Publication of JP2007535548A5 publication Critical patent/JP2007535548A5/ja
Application granted granted Critical
Publication of JP4685861B2 publication Critical patent/JP4685861B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2007510941A 2004-04-29 2005-04-27 ドーパミンアゴニストとしての３−ピペリジニルイソクロマン−５−オール Expired - Fee Related JP4685861B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56655704P 2004-04-29 2004-04-29
PCT/US2005/014487 WO2005111025A1 (en) 2004-04-29 2005-04-27 3-piperidinylisochroman-5-ols as dopamine agonists

Publications (3)

Publication Number Publication Date
JP2007535548A JP2007535548A (ja) 2007-12-06
JP2007535548A5 JP2007535548A5 (enExample) 2008-03-27
JP4685861B2 true JP4685861B2 (ja) 2011-05-18

Family

ID=34967397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007510941A Expired - Fee Related JP4685861B2 (ja) 2004-04-29 2005-04-27 ドーパミンアゴニストとしての３−ピペリジニルイソクロマン−５−オール

Country Status (11)

Country Link
US (1) US7919508B2 (enExample)
EP (1) EP1749001B1 (enExample)
JP (1) JP4685861B2 (enExample)
AR (1) AR050245A1 (enExample)
AT (1) ATE459618T1 (enExample)
DE (1) DE602005019719D1 (enExample)
DK (1) DK1749001T3 (enExample)
ES (1) ES2342083T3 (enExample)
PT (1) PT1749001E (enExample)
TW (1) TW200607802A (enExample)
WO (1) WO2005111025A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014339136C1 (en) * 2013-10-22 2019-10-31 Chiesi Farmaceutici S.P.A. Process for the preparation of a PDE4 inhibitor
CA2946990A1 (en) * 2014-04-28 2015-11-05 Pfizer Inc. Heterocyclic compounds and their use as dopamine d1 ligands
EA035544B1 (ru) * 2014-10-08 2020-07-03 Юсб Байофарма Спрл Производные тетрагидроизохинолина
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
SG10202100724UA (en) * 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
AU2017311691B2 (en) 2016-08-18 2021-12-02 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
MX2020000523A (es) * 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
CN111196781B (zh) * 2018-11-16 2023-07-28 湖南中南制药有限责任公司 一种改进的制备五氟利多的方法
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994486A (en) * 1989-05-31 1991-02-19 Abbott Laboratories Dopaminergic compounds
JPH04505619A (ja) * 1989-05-31 1992-10-01 アボツト・ラボラトリーズ ドーパミン作用物質
JP2001512436A (ja) * 1997-02-07 2001-08-21 アベンティス・ファーマスーティカルズ・インコーポレイテッド 抗精神病剤として有用な（４−ピペリジニル）−１ｈ−２−ベンゾピラン誘導体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004982A (en) * 1997-09-15 1999-12-21 Hoechst Marion Roussel, Inc. 4-piperidinyl) H-2-benzopyran derivatives useful as antipsychotic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994486A (en) * 1989-05-31 1991-02-19 Abbott Laboratories Dopaminergic compounds
JPH04505619A (ja) * 1989-05-31 1992-10-01 アボツト・ラボラトリーズ ドーパミン作用物質
JP2001512436A (ja) * 1997-02-07 2001-08-21 アベンティス・ファーマスーティカルズ・インコーポレイテッド 抗精神病剤として有用な（４−ピペリジニル）−１ｈ−２−ベンゾピラン誘導体

Also Published As

Publication number Publication date
ES2342083T3 (es) 2010-07-01
ATE459618T1 (de) 2010-03-15
US20070099955A1 (en) 2007-05-03
AR050245A1 (es) 2006-10-11
JP2007535548A (ja) 2007-12-06
DK1749001T3 (da) 2010-06-28
WO2005111025A1 (en) 2005-11-24
US7919508B2 (en) 2011-04-05
PT1749001E (pt) 2010-05-31
EP1749001B1 (en) 2010-03-03
TW200607802A (en) 2006-03-01
EP1749001A1 (en) 2007-02-07
DE602005019719D1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
US7320989B2 (en) Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US7238713B2 (en) Muscarinic agonists
US7335670B2 (en) Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics
US20080004312A1 (en) Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US6204260B1 (en) Non-peptidyl vasopressin V1a antagonists
AU2001259190A1 (en) Muscarinic agonists
EP1979318A1 (en) Amido compounds and their use as pharmaceuticals
CN103339108A (zh) 蛋白酶激活受体2(par2)拮抗剂
US8722896B2 (en) Prokineticin receptor antagonists and uses thereof
US8759342B2 (en) Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists
JP2007535548A (ja) ドーパミンアゴニストとしての３−ピペリジニルイソクロマン−５−オール
CN102015697B (zh) 酰胺衍生物以及含有该酰胺衍生物的药物组合物
JP2004277318A (ja) １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
US6784180B2 (en) Piperidines derivatives and their use as serotonin receptor antagonists
US7144898B2 (en) Indole derivatives for the treatment of depression and anxiety
US7521462B2 (en) 4-Amino-piperidine derivatives as monoamine uptake inhibitors
KR20030036834A (ko) 5-페닐벤질아민 화합물, 그의 제법 및 그의 합성 중간체
JP2008037850A (ja) 新規置換ピペリジン誘導体
JP2004277320A (ja) １，４−ジ置換ピペリジン誘導体およびそれを含有する医薬組成物
JP2008088057A (ja) Ｎ−置換−ｎ−（４−ピペリジニル）アミド誘導体
JPWO2005030722A1 (ja) Ｎ−置換−ｎ−（４−ピペリジニル）アミド誘導体
US6835733B2 (en) Tropane linked benzofuran derivatives
CN101405265A (zh) 酰氨基化合物及其作为药物的应用
EP1535912A1 (en) Muscarinic agonists
MX2008009668A (en) Amido compounds and their use as pharmaceuticals

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080208

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110126

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110210

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140218

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees